Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C18H21ClN4O9 |
| Molecular Weight | 472.834 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)O[C@@H]2[C@@H](COC(=O)C3=CC=C(C=C3)[N+]([O-])=O)OC(NC(=O)N(CCCl)N=O)[C@@H]2O1
InChI
InChIKey=YASNUXZKZNVXIS-CBNXCZCTSA-N
InChI=1S/C18H21ClN4O9/c1-18(2)31-13-12(9-29-16(24)10-3-5-11(6-4-10)23(27)28)30-15(14(13)32-18)20-17(25)22(21-26)8-7-19/h3-6,12-15H,7-9H2,1-2H3,(H,20,25)/t12-,13-,14-,15?/m1/s1
Bofumustine, also known as RFCNU was studied as an antitumor agent. Bofumustine participated in phase II trials in patients with digestive tract tumors. It was shown that 30% has remissions among which 13% were greater than 50%. In addition, bofumustine participated in phase II clinical trials, where it showed to be effective in 8% of digestive tumors, in 1 out of 7 pancreatic cancers and in 3 out of 10 hepatic and pulmonary metastases from an undiscovered primary adenocarcinoma. However, further information is not available.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals. | 1975 Dec 20 |
|
| In vivo enhancement of the experimental oncostatic effect of RFCNU by its encapsulation in liposomes. | 1981 Dec |
|
| Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNU. | 1982 Aug |
|
| [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)]. | 1982 Sep 16 |
|
| Cytostatic action of two nitrosoureas derived from cysteamine. | 1986 Nov |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C697
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000086345
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
55102-44-8
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
6P52D0J76B
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
100269
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
SUB05865MIG
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
DTXSID801023914
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL19887
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
279194
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
C80533
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY | |||
|
4838
Created by
admin on Fri Dec 15 16:05:54 GMT 2023 , Edited by admin on Fri Dec 15 16:05:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
